Publications by authors named "Sharon L Aukerman"

Claim this Profile
P
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
Emanuela Salvatorelli, Pierantonio Menna, Sekhar Surapaneni, Sharon L Aukerman, Massimo Chello

J Pharmacol Exp Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Emanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, Sekhar Surapaneni, Sharon L Aukerman

J Pharmacol Exp Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Vidya Mamidipudi, Tao Shi, Helen Brady, Sekhar Surapaneni, Rajesh Chopra, Sharon L Aukerman

Cancer Chemother Pharmacol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Paul W Hollenbach, Aaron N Nguyen, Helen Brady, Michelle Williams, Yuhong Ning, Sharon L Aukerman

PLoS One· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.
Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios V Georgakis, Anu Cherukuri, Sharon Lea Aukerman

Blood· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Daniel E Lopes de Menezes, Kimberly Denis-Mize, Yan Tang, Helen Ye, John C Kunich, Sharon L Aukerman

J Immunother· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel robust hepatitis C virus mouse efficacy model.
Qing Zhu, Yoko Oei, Dirk B Mendel, Evelyn N Garrett, Montesa B Patawaran, Sharon L Aukerman

Antimicrob Agents Chemother· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Daniel E Lopes de Menezes, Jing Peng, Evelyn N Garrett, Sharianne G Louie, Sang H Lee, Sharon L Aukerman

Clin Cancer Res· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
Sang Hoon Lee, Daniel Lopes de Menezes, Jayesh Vora, Alex Harris, Helen Ye, Sharon Lea Aukerman

Clin Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
Vijay Easwaran, Sang H Lee, Landon Inge, Lida Guo, Cheryl Goldbeck, Sharon L Aukerman

Cancer Res· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis